Results 191 to 200 of about 763,272 (322)

Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib. [PDF]

J Transl Med
Dewulf J, Navarro L, Dumauthioz N, Berdal M, Nagachinta S, Gaspariunaite V, Pombo Antunes AR, Lahoutte T, Massa S, Devoogdt N, D'Huyvetter M.   +10 more
europepmc   +1 more source

Application Progress of the Single Domain Antibody in Medicine. [PDF]

Int J Mol Sci, 2023
Tang H, Gao Y, Han J.
europepmc   +1 more source

PB1071 A Single-Domain Antibody Enhancing Protein S Activity Reduces Vaso-Occlusion in a Murine Model of Sickle Cell Disease

, 2023
Claire Auditeau, T. Maciel, Josepha-Clara Sedzro, Camille Roussel, A. Fricot-Montsinjon, Mohamed Choukri Khamari, Ivan Peyron, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis, Delphine Borgel, François Saller   +11 more
openalex   +1 more source

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan, John R. Mills, Paulina Vargas, Naveen K. Paramasivan, Connie E. Lesnick, Eati Basal, Surendra Dasari, James P. Fryer, Shannon R. Hinson, Joseph Laporta, Amy Espinal, Dennis Fitzgerald, Carolina Garcia, Anna E. Morenkova, Paola Pergami, Anna Shah, Andrew Knight, Reghann LaFrance Corey, Vanda A. Lennon, Anastasia Zekeridou, Sean J. Pittock, Divyanshu Dubey, Andrew McKeon   +22 more
wiley   +1 more source

Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design. [PDF]

Antib Ther
Wang M, Xu Q, Kong Y, Zhong Y, Yin F, Liu L, Yang Z, Ying T, Wu Y.   +8 more
europepmc   +1 more source

Persistent Leukoencephalopathy Following H1N1 Infection Associated With a Novel MYRF Variant (p.Gly735Asp)

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Mutations in myelin regulatory factor (MYRF) are linked to demyelinating disorders. We report a 38‐year‐old male who developed acute symmetric leukoencephalopathy mimicking a stroke following an influenza A virus infection. While clinical symptoms markedly improved with corticosteroids, MRI revealed persistent white matter lesions, contrasting
Jinghan Hu, Leiyun Huang, Wan Zhu, Min Peng, Qiang Gong, Jing Qian   +5 more
wiley   +1 more source

Guidelines in the Preparation of Fully Synthetic, Human Single-Domain Antibody Phage Display Libraries. [PDF]

Antibodies (Basel)
Tornetta MA, Whitaker BP, Cantwell OM, Haytko PN, Pisors ED, Zhou F, Chiu ML.   +6 more
europepmc   +1 more source

Evaluation of the Efficacy and Safety of Satralizumab in a Pregnant NMOSD Patient With AQP4/MOG‐IgG Dual Seropositive: A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley   +1 more source

Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool. [PDF]

PLoS One, 2023
Sawmynaden K, Wong N, Davies S, Cowan R, Brown R, Tang D, Henry M, Tickle D, Matthews D, Carr M, Bakrania P, Hoi Ting H, Hall G.   +12 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source